You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Hepatitis

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C

  • Technology appraisal guidance
  • Reference number: TA75
  • Published:  28 January 2004
  • Last updated:  27 November 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Appraisal Committee members and NICE project team
  • 9 Sources of evidence considered by the Committee
  • Appendix A Detail on criteria for audit of the use of interferon alfa (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
  • Update information

Update information

November 2013: This guidance has been partially updated by NICE technology appraisal guidance on peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300).

September 2010: This guidance has been partially updated by NICE technology appraisal guidance on peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200).

August 2006: This guidance is extended by NICE technology appraisal guidance on hepatitis C – peginterferon alfa and ribavirin (TA106).

ISBN: 978-1-4731-6982-1


Previous page Appendix A Detail on criteria for audit of the use of interferon alfa (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
Back to top